15	Sector:	Manufacturing	
	Sub-Sector:	Drugs and Medicines, and Medical Devices Manufacturing	
	Industry Classification[1]:	JSIC 165*	Medicines
		JSIC 1653	Biological preparations
		Pharmaceutical intermediates in JSIC Division E (Manufacturing), which relate to JSIC 165 and 1653.	
		JSIC 274*	Medical instruments and apparatus, and medical supplies
		JSIC 296*	Electronic equipment
		JSIC 2973*	Medical measuring instruments
	Obligations Concerned:	National treatment (Article 8.8)	
	Level of Government:	Central Government	
	Measures:	Foreign Exchange and Foreign Trade Law (Law No. 228 of 1949), Article 27[2]	
		Cabinet Order on Foreign Direct Investment (Cabinet Order No. 261 of 1980), Article 3	

[1] An asterisk (*) on the JSIC numbers indicates that the activities covered by this reservation under such numbers are limited to the activities related to manufacturing industry of agents against pathogenic organisms and parasites, their pharmaceutical intermediates and specially-controlled medical devices.

[2] For greater certainty, for the purposes of this reservation, the definition of "inward direct investment" provided in Article 26 of the Foreign Exchange and Foreign Trade Law applies with respect to the interpretation of this reservation.

Description[1]: <u>Investment liberalisation</u>

1. The prior notification requirement and screening procedures under the Foreign Exchange and Foreign Trade Law apply to foreign investors who intend to make investments in biological preparations manufacturing industry, manufacturing industry of agents against pathogenic organisms and parasites, and their pharmaceutical intermediates and manufacturing industry of specially-controlled medical devices and their accessories, and components of specially-controlled medical devices or their accessories in Japan.
2. The screening is conducted from the viewpoint of whether the investment is likely to cause a situation in which national security is impaired, the maintenance of public order is disturbed, or the protection of public safety is hindered.
3. The investor may be required to alter the content of the investment or discontinue the investment process, depending on the screening result.

[1] For the purposes of this reservation:
(a) "biological preparations manufacturing industry" deals with economic activities in an establishment which produces vaccine, serum, toxoid, antitoxin, and some preparations similar to the aforementioned products, or blood products;
(b) "agents against pathogenic organisms and parasites" means the pharmaceutical products which are categorised as agents against pathogenic organisms and parasites, and which have received marketing approval, under the laws and regulations of Japan; and
(c) "specially-controlled medical devices" means medical devices which have received marketing approval or certification as specially-controlled medical devices under the laws and regulations of Japan.